GlassScriptPhysician profile
Richard N Byrd
NPI 1700432861
$234.52
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $37.83.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $66.95 | 2021-2022 | |
| Clarus Therapeutics INC. | $52.66 | 2021 | |
| Teleflex LLC | $27.29 | 2021 | |
| Boston Scientific Corporation | $21.54 | 2022 | |
| Antares Pharma, INC. | $20.77 | 2021 | |
| Acerus Pharmaceuticals Corporation | $17.35 | 2021 | |
| Urovant Sciences INC | $14.87 | 2021 | |
| Olympus America INC. | $13.09 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.